Passionate about the use of AI and machine learning to change the risk, cost and timeline in the highly interdisciplinary field of personalized medicine.

Panna Sharma is the President, Chief Executive Officer and Board member of Lantern Pharma, a clinical stage oncology biotech using artificial intelligence (AI) and genomics to innovate the rescue, revitalization and development of precision cancer therapeutics. Lantern is focused on improving patient outcomes by using its proprietary AI platform – Response Algorithm for Drug Repositioning & Rescue (RADR™) – to rescue, revitalize and develop abandoned or failed cancer drugs, and to accelerate their development through precision trials that help identify patient groups more likely to respond to its pipeline of targeted cancer therapies.

As Chief Executive Officer, Panna is responsible for developing Lantern’s strategic vision, and working closely with the venture investors to raise capital that will place the Company at the forefront of using AI and genomics in developing its pipeline of precision therapies. The Lantern Pharma (LP) pipeline currently includes three drugs – two in clinical stages and one in preclinical, all focusing on cancers that have unique and unmet clinical needs with a clearly defined patient population. These drugs can be targeted to patients whose profile identifies them as having the highest probability of benefiting from the drug, thereby achieving better outcomes with reduced costs and accelerated timelines.

Prior to joining Lantern in 2018, Panna was the President and Chief Executive Officer of Cancer Genetics, Inc. (Nasdaq: CGIX), a provider of genomic and immune based cancer diagnostics and therapy development services some of the most prestigious medical institutions and pharma companies in the world. In his capacity as CEO at CGIX, he raised over $100 million in the public and private markets and grew the company from 25 employees in New Jersey to over 250 employees globally across multiple continents. Panna took CGIX public in 2013 and acquired four companies globally that help CGIX deliver on its mission to help personalize cancer treatment. Prior to CGIX, Panna founded TSG Partners, a specialty advisory group combining corporate strategy and corporate finance to create shareholder value for companies and investors in the life sciences, biotechnology and environmental sciences. Panna began his career as an industry analyst for financial services and technology companies, and was part of the management team that took the digital strategy and e-business company iXL public.

Panna attended Boston University in the University Professors Program having focused his studies on Philosophy of Science, Neural Networks and Artificial Intelligence. When not focused on the future of biotech, machine learning, emerging technologies and genomics, Panna can be found with his three children and wife and listening to music, attending sports functions, discussing new and ethical uses of AI, and enjoying the vibrant food scene in Atlanta.

Latest insights

Fri Mar 13 2020

Did an experimental drug help a U.S. coronavirus patient?

Fri Jan 10 2020

MoneyBall Medicine: Tom Davenport on the Analytics Gap in Healthcare

Wed Dec 18 2019

MoneyBall Medicine – Milind Kamkolkar on Seeing the Forest and the Tr...

Fri Nov 8 2019

Gini Deshpande of NuMedii on Augmented Intelligence for Drug Discovery

Never miss an announcement